Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety
British Journal of Dermatology2014Vol. 171(5), pp. 1099–1107
Citations Over TimeTop 10% of 2014 papers
Josep Malvehy, Axel Hauschild, Clara Curiel‐Lewandrowski, Peter Mohr, Rainer Hofmann‐Wellenhof, Richard Motley, Carola Berking, Douglas Grossman, John Paoli, Carmen Loquai, Judit Oláh, Uwe Reinhold, H Wenger, Thomas Dirschka, Suraj Davis, C. A. Henderson, Harold Rabinovitz, Julia Welzel, Dirk Schadendorf, Ulrik Birgersson
Abstract
Nevisense is an accurate and safe device to support clinicians in the detection of cutaneous melanoma.
Related Papers
- → Basal cell carcinoma: A comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis(1999)109 cited
- → Comparison of basal cell carcinoma subtypes observed in preoperative biopsy and Mohs micrographic surgery(2020)13 cited
- → Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients(1978)41 cited
- → Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium(1975)16 cited
- → Follow-up in advanced basal-cell carcinoma(2019)